SONN Company Profile and Key Details
Sonnet BioTherapeutics
Price Chart
Stock Price Today
Sonnet BioTherapeutics Holdings, Inc. (SONN) stock declined over -59.35%, trading at $1.26 on NASDAQ, down from the previous close of $3.10. The stock opened at $3.16, fluctuating between $1.26 and $3.23 in the recent session.
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Dec 02, 2025 | 3.16 | 3.23 | 1.26 | 1.26 | 8.64M |
| Dec 01, 2025 | 3.83 | 3.92 | 3.10 | 3.10 | 892.55K |
| Nov 28, 2025 | 4.15 | 4.25 | 3.66 | 3.72 | 418.25K |
| Nov 26, 2025 | 4.21 | 4.24 | 3.56 | 4.16 | 1.37M |
| Nov 25, 2025 | 4.70 | 4.96 | 4.13 | 4.16 | 658.74K |
| Nov 24, 2025 | 4.46 | 5.06 | 4.40 | 4.85 | 582.98K |
| Nov 21, 2025 | 4.28 | 4.58 | 3.95 | 4.55 | 633.46K |
| Nov 20, 2025 | 4.60 | 4.69 | 4.12 | 4.41 | 613.38K |
| Nov 19, 2025 | 4.98 | 5.07 | 4.20 | 4.51 | 642.81K |
| Nov 18, 2025 | 5.17 | 5.45 | 4.66 | 4.89 | 755.14K |
| Nov 17, 2025 | 5.80 | 5.95 | 4.75 | 5.35 | 873.59K |
| Nov 14, 2025 | 4.43 | 5.95 | 4.05 | 5.92 | 1.48M |
| Nov 13, 2025 | 4.62 | 5.44 | 4.42 | 5.40 | 996.91K |
| Nov 12, 2025 | 4.54 | 4.82 | 4.30 | 4.76 | 513.63K |
| Nov 11, 2025 | 4.36 | 4.62 | 3.72 | 4.60 | 515.65K |
| Nov 10, 2025 | 5.04 | 5.14 | 4.41 | 4.46 | 537.42K |
| Nov 07, 2025 | 4.10 | 4.98 | 4.06 | 4.87 | 782.69K |
| Nov 06, 2025 | 4.40 | 4.66 | 4.02 | 4.22 | 529.12K |
| Nov 05, 2025 | 3.50 | 4.72 | 3.21 | 4.55 | 1.46M |
| Nov 04, 2025 | 4.04 | 4.07 | 3.12 | 3.20 | 898.3K |
Contact Details
About Company
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company based in Princeton, New Jersey, operates in the clinical stage with a primary focus on oncology. The firm is dedicated to developing novel platforms for creating biologic medicines that can exhibit either singular or dual therapeutic mechanisms. Central to their strategy is a proprietary fully human albumin binding technology. This innovative system employs human single-chain antibody fragments specifically engineered to bind to human serum albumin, leveraging it for enhanced delivery and transport to target tissues. Their leading therapeutic candidate, SON-1010, is a fully human variant of interleukin 12, currently being advanced for the treatment of non-small cell lung cancer and cancers affecting the head and neck. Additionally, Sonnet is progressing SON-080, another fully human interleukin 6 formulation, intended to address both chemotherapy-induced and diabetic peripheral neuropathy. The company also maintains a licensing agreement with New Life Therapeutics PTE, LTD., for the development and commercialization of pharmaceutical preparations containing a specific recombinant human interleukin 6.
Company Information
| Employees | 13 |
| Beta | 1.47 |
| Sales or Revenue | $1.00M |
| 5Y Sales Change% | -1% |
| Fiscal Year Ends | September |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
Frequently Asked Questions
Chief Financial Officer
Mr. Donald J. Griffith CPA, CPA
Controller & Director
Dr. Pankaj Mohan Ph.D.
Founder, Chairman, Chief Executive Officer & Pres
Ms. Susan Dexter
Chief Technical Officer
Mr. Manuel Dafonseca
Head of Clinical Operations
Dr. Richard T. Kenney FACP, M.D.
Chief Medical Officer
Dr. John K. Cini Ph.D.
Chief Scientific Officer & Co-Founder
Mr. Donald J. Griffith C.P.A., CPA
Controller & Director
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep